RegulationOrphan Drug (United States), Orphan Drug (European Union), Priority Review (China), Breakthrough Therapy (China), Orphan Drug (Japan), Special Review Project (China)

Structure/Sequence

Molecular FormulaC34H40F6N12O3

InChIKeyGJMQTRCDSIQEFK-SCDRJROZSA-N

CAS Registry2050057-56-0

202

Clinical Trials associated with Upadacitinib hemihydrate

NCT07352566

/ Not yet recruitingPhase 4IIT

Utilization of a Cutaneous Therapy In Situ Microdevice

This study is being done to test a microdevice, which is a small device designed to test drugs directly on skin conditions like atopic dermatitis (eczema) and psoriasis.
The small device, about the size of a grain of rice, has up to 20 tiny reservoirs that hold medications that are approved by the Food and Drug Administration (FDA) for atopic dermatitis and psoriasis. Very small amounts of these medications will be released into the skin (at levels in your body much lower than are typically used). In this study, the device will be tested to see if it's safe and works well for predicting how the skin will react to standard treatments. We will also look at how these reactions are connected to genetic information and overall treatment results.

Start Date01 Aug 2026

Sponsor / Collaborator

The University of California, San Francisco

NCT07636057

/ Not yet recruitingPhase 4IIT

Effectiveness and Safety of Tofacitinib Versus Upadacitinib as Add-on to Methotrexate in Rheumatoid Arthritis; Comparative Clinical Study

The goal of this interventional study is to learn, whether Tofacitinib or upadacitinib is more effective in treating the patients of Rheumatoid Arthritis. It will also learn about the safety of these two agents. The main questions it aims to answer are:
* Which JAK inhibitor (Tofacitinib or Upadacitinib) is more effective to improve the disease activity of Rheumatoid arthritis in Pakistani population?
* What is the Disease Activity scores, ESR, CRP, RA factor level of patients?
* What are the side effects of both drugs, during the study time?
Participants:
* Of Group A will be taking 5mg Tofacitinib oral daily for 6 months along with 25mg of once weekly dose of oral Methotrexate, whereas of Group B will be taking 15mg Upadacitinib oral daily for 6 months along with 25mg of once weekly dose of oral methotrexate.
* Will Visit the clinic once at 3 months and then 6 months for checkups and tests
* Will Keep a diary of any infection, treatment taken, duration of infection
* Will inform the researcher about any unusual side effect during the study

Start Date05 Jul 2026

Sponsor / Collaborator

Sheikh Zayed Federal Postgraduate Medical Institute

NCT07588568

/ Not yet recruitingPhase 2IIT

A Trial of Upadacitinib for Non-responsive Eosinophilic Esophagitis (ATUNE)

The goal of this study is to find out if a medication called upadacitinib can help treat a condition called Eosinophilic Esophagitis (EoE).
The main question it aims to answer are:
- Does upadacitinib in addition to topical corticosteroids help reduce EoE disease activity?
Participants will:
* Take upadacitinib or placebo every day for 12 weeks, followed by 12 weeks of upadacitinib
* Fill out surveys and answer health questions
* Visit the clinic every 4 weeks for checkups and tests

Start Date01 Jul 2026

Sponsor / Collaborator

The University of North Carolina at Chapel Hill

[+2]

100 Clinical Results associated with Upadacitinib hemihydrate

100 Translational Medicine associated with Upadacitinib hemihydrate

100 Patents (Medical) associated with Upadacitinib hemihydrate

1,791

Literatures (Medical) associated with Upadacitinib hemihydrate

31 Dec 2026·JOURNAL OF DERMATOLOGICAL TREATMENT

Dose-dependent effectiveness and patient-reported outcomes with JAK1 inhibitors in atopic dermatitis: a 36-week multicenter real-world cohort

Article

Author: Ulutaş Demirbaş, Gözde ; Esen, Mustafa ; Diremsizoglu, Esin ; Demirbaş, Abdullah

BACKGROUND:

Dose-stratified real-world data for JAK1 inhibitors in AD are limited.

OBJECTIVE:

To compare effectiveness and safety of standard vs high doses of abrocitinib and upadacitinib in routine care.

METHODS:

Multicenter, retrospective cohort study. The primary endpoint was Week-12 achievement of Eczema Area and Severity Index (EASI)-75. Secondary outcomes included patient-reported improvements at Minimal Clinically Important Difference (MCID) thresholds, Minimal Disease Activity (MDA) at Week 36, time-to-EASI-75, and treatment-emergent adverse events(TEAE).

RESULTS:

A total of 124 patients were analyzed (abrocitinib 100 mg, n = 28; abrocitinib 200 mg, n = 32; upadacitinib 15 mg, n = 30; upadacitinib 30 mg, n = 34). At Week 12, EASI-75 was achieved in 20/32 (62.5%) versus 10/28 (35.7%) for abrocitinib (OR 2.94, 95% CI 1.06-8.15; p = 0.036) and in 22/34 (64.7%) versus 14/30 (46.7%) for upadacitinib (OR 2.92, 95% CI 1.16-7.38; p = 0.021), favoring the higher-dose regimens. Itch improvement was more frequent with higher doses. By Week 36, full minimal disease activity was observed in 30.2% of patients receiving abrocitinib 200 mg and 26.7% receiving upadacitinib 30 mg, compared with 18.4% and 20.0% in the lower-dose groups. Kaplan-Meier analysis showed faster responses with high doses (median 12 vs 36 weeks; log-rank p < 0.01). Safety was comparable across groups.

CONCLUSION:

High-dose JAK1 regimens achieve faster, numerically greater disease control without short-term safety tradeoffs, supporting escalation in suboptimal responders.

31 Dec 2026·JOURNAL OF DERMATOLOGICAL TREATMENT

From signal to strategy: a disproportionality analysis of dupilumab-associated rosacea in FAERS with a summary of reported clinical cases

Review

Author: Yang, Xuefan ; Ruan, Dandan ; Li, Sitong ; Chen, Xiang ; Lin, Jiacheng ; Qiu, Xinlan ; Li, Jiaqi ; Ju, Qiang ; Mo, Xiaohui

PURPOSE:

Emerging evidence suggests rosacea as a recognizable adverse event during dupilumab therapy. This study aimed to investigate the potential association between dupilumab and rosacea using pharmacovigilance data and to characterize the clinical features of dupilumab-associated rosacea (DAR) through a review of reported cases.

MATERIALS AND METHODS:

We utilized the FDA Adverse Event Reporting System (FAERS) database (2017-2024) to identify disproportionality signals using four methods: Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Information Component (IC), and Empirical Bayesian Geometric Mean (EBGM). To contextualize these findings, we performed a focused narrative review of 8 publications comprising 10 DAR cases with extractable individual data.

RESULTS:

A significant disproportionality signal was identified across all four methods (ROR 3.873; PRR 3.872; IC 1.865 with IC025 1.653; EBGM 3.642), with reports predominantly in adults and females. In the case review, a consistent phenotype emerged: papulopustules on persistent centrofacial erythema with frequent burning; facial predominance with occasional extension to neck, scalp, or upper trunk; frequent Demodex detection by scraping, KOH, or in vivo imaging; and occasional granulomatous histology. Onset ranged from approximately 2 weeks to 21 months, including one post-discontinuation case. Most patients improved with rosacea-directed therapy (topical ivermectin or metronidazole; anti-inflammatory-dose doxycycline). However, dechallenge or rechallenge patterns and the need for dose-interval extension, temporary interruption, or switching biologic (e.g., lebrikizumab, upadacitinib) in a subset support a drug-related pattern at the reporting level.

CONCLUSIONS:

DAR represents a distinct clinical entity from dupilumab-associated head and neck dermatitis, which is eczematous and typically responds to antifungals or calcineurin inhibitors. While disproportionality signals indicate association rather than incidence or causality and are subject to reporting bias, clinicians should be aware of this potential adverse event to ensure appropriate management.

31 Dec 2026·JOURNAL OF DERMATOLOGICAL TREATMENT

Distinct ocular safety profiles of dupilumab and upadacitinib in atopic dermatitis: a real-world study with ophthalmological and microbiological assessment

Article

Author: Pastuszczak, Maciej ; Stepinska, Paulina ; Zawadzinska-Halat, Kamila

BACKGROUND:

Dupilumab is highly effective in atopic dermatitis (AD) but is associated with ocular surface disease, whereas Janus kinase (JAK) inhibitors may have a more favorable ocular safety profile.

OBJECTIVES:

To compare ocular outcomes and conjunctival microbiology in patients with moderate-to-severe AD treated with dupilumab versus upadacitinib.

METHODS:

In this prospective real-world study, adult patients were treated with dupilumab or upadacitinib and evaluated at baseline and after 16 weeks. Ocular assessment included the Ocular Surface Disease Index (OSDI) and Schirmer test. Conjunctival swabs were collected for culture. Dermatological outcomes were assessed using EASI and DLQI.

RESULTS:

Ninety-six patients were included (upadacitinib, n = 52; dupilumab, n = 44). Both treatments significantly improved EASI and DLQI. Conjunctivitis occurred in 39.0% of dupilumab-treated patients and in none of the upadacitinib-treated patients (p < .001). OSDI improved with upadacitinib (-8.3) but worsened with dupilumab (+2.1) (p < .001). Schirmer test results and bacterial colonization did not differ between groups.

CONCLUSIONS:

Dupilumab and upadacitinib showed comparable dermatological efficacy but distinct ocular safety profiles. Dupilumab was associated with more frequent conjunctivitis and worsening ocular symptoms.

529

News (Medical) associated with Upadacitinib hemihydrate

09 Jun 2026

·www.fiercepharma.com

AbbVie’s Skyrizi narrowly slides ahead of J&J’s Tremfya in May drug ad spending rankings

Johnson & Johnson's Tremfya was sandwiched between two AbbVie immunology drugs in the top three ad spending rankings from May. AbbVie’s Skyrizi again held onto its top spot on the TV ad spender leaderboard for the month of May, but overall spend across the stable top three is falling. Despite its lower spending, Skyrizi narrowly eked back into the top spot for the second consecutive month, spending $38.9 million on May ads, according to data shared with Fierce Pharma Marketing by analysts at iSpot.tv. This total makes for a $7.3 million decrease from the previous month’s spend. Johnson & Johnson and its rival immunology med Tremfya was, as usual, right on Skyrizi's tail in May, coming in second by a very small margin. The company shelled out $38.8 million on May Tremfya ads, which declined as well from April’s $39.7 million. Sandwiching J&J, another AbbVie immunology competitor came in third with its Rinvoq. AbbVie dedicated $29.6 million to Rinvoq’s TV ads in May, a nearly $10 million step down from the $39.5 million showing in April. Eli Lilly maintained its fourth-place spot for obesity med Zepbound, putting down $22.7 million on seven ads. Meanwhile, Johnson & Johnson’s atypical antipsychotic Captyla usurped Regeneron and Sanofi’s immunology megablockbuster Dupixent for fifth, sending Dupixent and its $16.3 million spending down to sixth place as a result. Lundbeck and Otsuka’s depression drug Rexulti and Eli Lilly and Boehringer Ingelheim’s diabetes and kidney disease treatment Jardiance held down their spots from April in seventh and eighth place, respectively. Jardiance and the other two drugs at the bottom of the list are the only ones to increase their spending in May, marking a switch-up from April, when the majority of top TV drug ad spenders hiked up their advertising budgets. Rounding out the rankings, AbbVie’s atypical antipsychotic Vraylar made another appearance in the ninth slot after clawing on the leaderboard in April. The last spot on the list went to a tardive dyskinesia and chorea associated with Huntington’s disease drug, as it did in April, but this time it was Teva’s Austedo that made the grade instead of Neurocrine’s Ingrezza. Teva’s rival drug upped its spending the most out of any on the list, with a 2.7 million boost from April. Check out May’s biggest ad spenders below, based on data compiled by analysts at iSpot.tv.1. Skyrizi Movement: No changeWhat is it? AbbVie’s immunology drug Est. national linear TV ad spend: $38.9 million (down from $46.2 million in April)UC/Crohn’s disease: $20.5 millionPsoriasis: $16.4 millionPsoriatic arthritis: $1.9 millionTop TV network by spend share of voice (SOV): NBC (20.43%)Top TV program by spend SOV: NBA (9.21%) Number of spots: Six (one psoriatic arthritis, three psoriasis, two UC/Crohn’s disease) Biggest-ticket ad: “I'm All In: Swimming Pool” (est. $10.6 million) 2. Tremfya Movement: No changeWhat is it? Johnson & Johnson’s immunology drugEst. national linear TV ad spend: $38.8 million (down from $39.7 million in April)UC/Crohn’s disease: $21.8 millionPsoriasis: $1.5 millionPsoriatic arthritis: $15.5 millionTop TV network by spend SOV: ABC (24.58%)Top TV program by spend SOV: Good Morning America (7.43%)Number of spots: Five (two psoriatic arthritis, two psoriasis, one UC/Crohn’s disease) Biggest-ticket ad: “Relentless Weed” (est. $21.8 million) 3. Rinvoq Movement: No movementWhat is it? AbbVie’s JAK inhibitor immunology drug Est. national linear TV ad spend: $29.6 million (down from $39.5 million in April)Arthritis: $9.2 millionEczema: $8.8 millionUC/Crohn’s disease: $11.6 millionTop TV network by spend SOV: ABC (21.90%)Top TV program by spend SOV: Today (2.76%) Number of spots: Three (one arthritis, one UC/Crohn’s disease, one eczema)Biggest-ticket ad: “Classic Car, Tennis and Fire Station” (est. $11.6 million) 4. Zepbound Movement: No movementWhat is it? Eli Lilly’s obesity drugEst. national linear TV ad spend: $22.7 million (down from $24.4 million in April)Top TV network by spend SOV: CBS (30.07%)Top TV program by spend SOV: NBA (16.31%)Number of spots: Seven Biggest-ticket ad: “Watch This: Data” (est. $10.3 million) 5. CaplytaMovement: Up one spotWhat is it? Johnson & Johnson’s atypical antipsychotic drugEst. national linear TV ad spend: $19 million (down from $20.2 million in April)Top TV network by spend SOV: ABC (15.58%)Top TV program by spend SOV: Good Morning America (5.79%)Number of spots: ThreeBiggest-ticket ad: “Let in the Lyte: More Relief” (est. $7.3 million) 6. DupixentMovement: Down one spotWhat is it? Sanofi and Regeneron’s immunology drugEst. national linear TV ad spend: $16.3 million (down from $20.4 million in April)Eczema: $8.2 millionAsthma: $8 millionGastrointestinal: $51.4KTop TV network by spend SOV: ABC (27.49%)Top TV program by spend SOV: NBA (15.64%) Number of spots: Eight (three asthma, four eczema, one gastrointestinal) Biggest-ticket ad: “Better Days” (est. $6.2 million) 7. Rexulti Movement: No movementWhat is it? Lundbeck and Otsuka’s neurology drugEst. national linear TV ad spend: $14.2 million (down from $17.8 million in April)Top TV network by spend SOV: CBS (15.15%)Top TV program by spend SOV: NCIS (4.73%) Number of spots: One Biggest-ticket ad: “Progress” (est. $14.2 million) 8. JardianceMovement: No movementWhat is it? Eli Lilly and Boehringer Ingelheim’s diabetes and kidney disease drugEst. national linear TV ad spend: $13.4 million (up from $12.6 million in April)CKD: $3.1 millionDiabetes: $10.3 millionTop TV network by spend SOV: ABC (17.58%)Top TV program by spend SOV: Gunsmoke (4.05%)Number of spots: Two (one CKD, one diabetes)Biggest-ticket ad: “Behind the Scenes” (est. $10.3 million) 9. VraylarMovement: No movementWhat is it? AbbVie’s atypical antipsychoticEst. national linear TV ad spend: $12.7 million (up from $12.1 million in April)Bipolar: $2.7 millionDepression: $10.1 millionTop TV network by spend SOV: CBS (14.24%)Top TV program by spend SOV: ABC World News Tonight With David Muir (4.58%)Number of spots: Three (two depression, one bipolar)Biggest-ticket ad: “Jane’s Head” (est. $10 million) 10. AustedoMovement: Not listed last monthWhat is it? Teva’s Huntington’s disease chorea or tardive dyskinesia drugEst. national linear TV ad spend: $11.9 million (up from $9.2 million in April)Top TV network by spend SOV: CBS (33.41%)Top TV program by spend SOV: Today With Jenna & Sheinelle (7.63%)Number of spots: TwoBiggest-ticket ad: “Derek” (est. $6.4 million)

ADCFinancial Statement

02 Jun 2026

·www.fiercebiotech.com

Abivax stock suffers as cancer cases overshadow stellar efficacy in ulcerative colitis phase 3 trial

Abivax plans to file for FDA approval toward the end of the year. \n Abivax has raised the efficacy bar in ulcerative colitis, linking obefazimod to a 40%, placebo-adjusted jump in clinical remission rates in a phase 3 trial. But the share price of the biotech, a reported takeover target for several Big Pharmas, collapsed after several patients on the high dose developed cancers. Paris-based Abivax emerged as a top M&A target last year, with AstraZeneca and Eli Lilly reportedly among the companies interested in a deal that could be worth $18 billion, after reporting eight-week data from a phase 3 trial of obefazimod. The data suggested the small molecule, which upregulates miR-124 in immune cells, could disrupt the huge, highly competitive inflammatory bowel disease market. With Abivax, which has indicated an interest in partnering obefazimod outside the U.S., waiting for the 48-week data before pursuing a deal, the maintenance readout has emerged as a key moment for the biotech and its suitors. Investors, primed for strong efficacy results, reacted badly to the data.The 25 mg and 50 mg once-daily obefazimod doses performed significantly better than placebo, hitting clinical remission rates of 50.8% and 51.3%, respectively, at Week 44 versus 10.4% in the control arm. At 39.3% and 40.3%, the placebo-adjusted clinical remission rates are below the 48% Abivax reported at Week 48 of its phase 2 open-label extension study but above the bar set by existing oral and biologic treatments. Per Abivax’s presentation (PDF), the 39% placebo-adjusted clinical remission maintenance rate after 52 weeks on AbbVie’s oral JAK inhibitor Rinvoq is the only comparable result, with the caveat that cross-trial comparisons can be unreliable. Pfizer’s Velsipity is the next closest challenger, with a placebo-adjusted clinical remission rate of 32%. Abivax achieved the efficacy in a population with many patients who were refractory to multiple other lines of therapy. About 40% of patients had tried advanced therapy before joining the trial. Talking on an Abivax call about how to compare the data, David Rubin, M.D., a gastroenterologist at the University of Chicago, questioned how many patients in the other studies were refractory to multiple drugs.Rinvoq’s label has (PDF) a boxed warning with five safety warnings, including a higher rate of all-cause mortality. The phase 3 data suggest obefazimod is free from many of the safety problems associated with AbbVie’s drug. Abivax reported placebo-like infection rates and numerically more treatment-emergent adverse events leading to discontinuations on placebo than on either obefazimod dose. However, there was one case each of prostate cancer, breast cancer and colonic dysplasia on the high dose, compared to zero cases on the low dose or placebo. Abivax also reported two cases each of basal and squamous cell carcinoma on the high dose. There was one case of basal cell carcinoma on placebo and one case of squamous cell carcinoma on the low dose. The cancer cases may explain why Abivax’s share price fell about 28% to $92.80 in premarket trading. Yet Rubin, echoing points made by Abivax executives, said the cancer cases are “not worrisome,” adding that “there\'s no signal.” Chris Rabbat, Ph.D., global head of medical affairs at Abivax, said the findings observed “are well within the range of what could be expected” for the patient population. Abivax plans to file for FDA approval toward the end of the year. The biotech expects to publish phase 2b induction data in Crohn’s disease in mid-2027. Rubin said he “fully” expects obefazimod’s mechanism to work in Crohn’s.

Clinical ResultPhase 3Phase 2

02 Jun 2026

·firstwordpharma.com

Abivax colitis drug hits goal, but cancer cases rattle investors

The subject of rumours earlier this year that Eli Lilly was interested in a multibillion-dollar takeover, Abivax this week unveiled a key trial readout that investors had been waiting to see for its ulcerative colitis (UC) candidate obefazimod before a planned FDA filing.Instead of celebrating, however, investors sent the French biotech's shares tumbling more than 32% on Tuesday after results from the ABTECT maintenance trial revealed several cancer cases among patients receiving the higher dose of the oral miR-124 enhancer. The safety concerns overshadowed what was otherwise a successful Phase III readout, according to analysts.The study enrolled 580 patients who had responded to treatment in the ABTECT-1 and ABTECT-2 induction trials reported last year. Those earlier studies showed that the higher 50-mg dose of obefazimod had met the primary endpoint of clinical remission at week eight, with pooled remission rates of 16.4% versus placebo.Remissions rates around 40%On Monday, Abivax announced that after 44 weeks of once-daily obefazimod, placebo-adjusted clinical remission rates were 39.3% and 40.3% in the 25-mg and 50-mg dose arms, respectively, achieving the primary endpoint of the maintenance study.Both doses met all key secondary endpoints as well. Placebo-adjusted rates for the lower and higher doses, respectively, were 42.5% and 51% for endoscopic improvement; 31.4% and 37.8% for endoscopic remission; and 35.1% and 38% for corticosteroid-free remission."The totality of the data reinforces obefazimod's potential to meaningfully change the treatment landscape for ulcerative colitis," Chief Medical Officer Fabio Cataldi said in a release Monday. The company plans to submit an FDA filing in the fourth quarter.Seven cancer casesHowever, attention quickly shifted to the trial's safety findings. Among patients receiving the 50-mg dose, investigators reported one case each of prostate cancer, breast cancer and colonic dysplasia, along with four cases of non-melanoma skin cancer (NMSC) divided evenly between basal cell and squamous cell carcinoma.Abivax said the prostate, breast and colon cases were "considered unrelated to treatment by investigators, and no organ-specific clustering was observed." For the skin cancers, the company noted that two cases were judged not or unlikely related to treatment; and of the remaining two cases, one had a prior history of skin cancer. The average age of patients who developed skin cancer was 62 years, compared to 42 years across the broader study population, a difference Abivax said was consistent with age-related risk of NMSC.'Complicates matters'Still, analysts said the findings could pose an obstacle as regulators — and potential M&A suitors — scrutinise the data package. "[The] cancer signal complicates matters," Jefferies analysts said. "Even if unrelated noise, we think the overhang will be real, especially considering absence of other value-inflecting data events over the next [year]."Damien Choplain of Stifel struck a more optimistic tone. "While the malignancy signal cannot be ignored, we view it as a potential labelling overhang rather than evidence of a clear causal safety risk," he said, adding that the efficacy results for obefazimod remained strong. He pointed out that other inflammatory disease drugs, such as AbbVie's oral JAK inhibitor Rinvoq (upadacitinib), carry malignancy warnings yet were nevertheless still commercially successful. Rinvoq itself had sales of $8.3 billion last year.In January, speculation surfaced that Eli Lilly was preparing a bid for Abvivax worth €15 billion ($17.5 billion), with one report suggesting the US pharma was weighing potential regulatory hurdles in France before moving forward.Abivax CEO Marc de Garidel declined at the time to comment on whether Lilly had approached his company, but said it would seek a partner to market obefazimod outside the US. More recently, he indicated that Abivax was in no hurry on the acquisition front despite the takeover chatter.

Clinical ResultPhase 3AcquisitionASCOPhase 1

100 Deals associated with Upadacitinib hemihydrate

External Link

KEGG	Wiki	ATC	Drug Bank
D10994 D11048	Upadacitinib hemihydrate	L04AA44	DB15091

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Giant Cell Arteritis	European Union	AbbVie Deutschland GmbH & Co. KG	08 Apr 2025
Giant Cell Arteritis	Iceland	AbbVie Deutschland GmbH & Co. KG	08 Apr 2025
Giant Cell Arteritis	Liechtenstein	AbbVie Deutschland GmbH & Co. KG	08 Apr 2025
Giant Cell Arteritis	Norway	AbbVie Deutschland GmbH & Co. KG	08 Apr 2025
Polyarticular Juvenile Idiopathic Arthritis	United States	AbbVie, Inc.	26 Apr 2024
Crohn's disease, active moderate	European Union	AbbVie Deutschland GmbH & Co. KG	24 Apr 2023
Crohn's disease, active moderate	Iceland	AbbVie Deutschland GmbH & Co. KG	24 Apr 2023
Crohn's disease, active moderate	Liechtenstein	AbbVie Deutschland GmbH & Co. KG	24 Apr 2023
Crohn's disease, active moderate	Norway	AbbVie Deutschland GmbH & Co. KG	24 Apr 2023
Crohn's disease, active severe	European Union	AbbVie Deutschland GmbH & Co. KG	24 Apr 2023
Crohn's disease, active severe	Iceland	AbbVie Deutschland GmbH & Co. KG	24 Apr 2023
Crohn's disease, active severe	Liechtenstein	AbbVie Deutschland GmbH & Co. KG	24 Apr 2023
Crohn's disease, active severe	Norway	AbbVie Deutschland GmbH & Co. KG	24 Apr 2023
Moderate Atopic Dermatitis	United States	AbbVie, Inc.	14 Jan 2022
Severe Atopic Dermatitis	United States	AbbVie, Inc.	14 Jan 2022
Crohn Disease	Canada	AbbVie AS	16 Jan 2020
Ankylosing Spondylitis	European Union	AbbVie Deutschland GmbH & Co. KG	16 Dec 2019
Ankylosing Spondylitis	Iceland	AbbVie Deutschland GmbH & Co. KG	16 Dec 2019
Ankylosing Spondylitis	Liechtenstein	AbbVie Deutschland GmbH & Co. KG	16 Dec 2019
Ankylosing Spondylitis	Norway	AbbVie Deutschland GmbH & Co. KG	16 Dec 2019

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Alopecia Areata	NDA/BLA	United States	AbbVie, Inc.	28 Apr 2026
Nonsegmental vitiligo	NDA/BLA	United States	AbbVie, Inc.	03 Feb 2026
Nonsegmental vitiligo	NDA/BLA	European Union	AbbVie, Inc.	03 Feb 2026
Pediatric Crohn's Disease	Phase 3	United States	AbbVie, Inc.	08 Aug 2024
Pediatric Crohn's Disease	Phase 3	China	AbbVie, Inc.	08 Aug 2024
Pediatric Crohn's Disease	Phase 3	Japan	AbbVie, Inc.	08 Aug 2024
Pediatric Crohn's Disease	Phase 3	Australia	AbbVie, Inc.	08 Aug 2024
Pediatric Crohn's Disease	Phase 3	Belgium	AbbVie, Inc.	08 Aug 2024
Pediatric Crohn's Disease	Phase 3	Brazil	AbbVie, Inc.	08 Aug 2024
Pediatric Crohn's Disease	Phase 3	Bulgaria	AbbVie, Inc.	08 Aug 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05814627 (SELECT-SWITCH, Pubmed \| Ann Rheum Dis)	Phase 3	Rheumatoid Arthritis	492	Upadacitinib	dikowbdlmj(luzeyrddck) = feuebkxbvx bikwrpnzzn (wzrkltaext ) View more	Positive	01 Apr 2026
				Adalimumab	dikowbdlmj(luzeyrddck) = kltkbjaupc bikwrpnzzn (wzrkltaext ) View more
AAD2026	Not Applicable	Skin Diseases	103,275	Upadacitinib	wipzdlxpfx(emdcuvlfmd) = median onset ranged from 103 to 358 days across drugs, with early-failure type pattern ( 31), indicating AE rates declined over time. Tofacitinib cumulative AE curve differed significantly from others (adj.p 3C2e-16). dkatjzwayv (daladkfwez ) View more	Positive	27 Mar 2026
				Baricitinib
AAD2026	Not Applicable	Dermatitis, Atopic	504	Upadacitinib (Atopic Dermatitis)	mldzamphcr(lpvfvstjwk) = doinmtydjd jphsdozpyd (bnxyobfppc ) View more	Positive	27 Mar 2026
AAD2026	Not Applicable	Dermatitis, Atopic	1,092	Lebrikizumab	syckxchrvh(wlpgbvofzo) = uoagkugdtf ygwrjdbdpz (ntjnsmixal ) View more	Positive	27 Mar 2026
				Nemolizumab	syckxchrvh(wlpgbvofzo) = dlczfsaatn ygwrjdbdpz (ntjnsmixal ) View more
AAD2026	Not Applicable	Dermatitis, Atopic	3,009	Upadacitinib	dentpoayjd(owzfpmhjmb): RR = 1.64 (95.0% CI, 1.23 - 2.17), P-Value = 0.0007 View more	Positive	27 Mar 2026
				Dupilumab
AAD2026	Not Applicable	Moderate Atopic Dermatitis	189	Upadacitinib (bio-naïve)	stgbduuino(gmplshcjrj) = atjggfqcrz xxwwyzwqys (ualfiagpns ) View more	Positive	27 Mar 2026
				Upadacitinib (bio-experienced)	stgbduuino(gmplshcjrj) = sdzzvedvnb xxwwyzwqys (ualfiagpns ) View more
AAD2026	Not Applicable	Severe Atopic Dermatitis	24	Upadacitinib (Severe Atopic Dermatitis)	ywpemermyj(axljbiggzt) = dssbseyoaz mbdyuhozko (inuypihcnx ) View more	Positive	27 Mar 2026
NCT06012240 (AAD2026)	Phase 1	Alopecia Areata	12	Upadacitinib	rbnpmwnvyr(tflylviwbr) = dwotdqqpau tefcoyxfuf (caqnonjveu ) View more	Positive	27 Mar 2026
AD-VISE (AAD2026)	Not Applicable	Dermatitis, Atopic	1,159	Upadacitinib	vgbbagbjnj(kzmbgixzlz) = tkccqdmtmf nnwvcxmbbj (yruktcskpd ) View more	Positive	27 Mar 2026
AAD2026	Not Applicable	-	4	Upadacitinib (Steroid-Refractory Immune-Related Cutaneous Adverse Events)	nvsyvjheuy(gasbaixpad) = No patients experienced progression of underlying malignancy, and in two cases serial PET/CT scans showed continued improvement (patients still on therapy >12 weeks). hhdmsrdkrp (wzesmyefea )	Positive	27 Mar 2026

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis